Drug Profile
MRx 102
Alternative Names: MRx-102Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator MyeloRx
- Class
- Mechanism of Action DNA helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia; Cancer; Lymphoma; Malignant melanoma
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Lymphoma
- No development reported Malignant melanoma
Most Recent Events
- 14 Sep 2023 MRx 102 is still in preclinical trials for Acute myeloid leukaemia in USA (Unspecified route) (MyeloRx pipeline, September 2023)
- 14 Sep 2023 MRx 102 is still in preclinical trials for Lymphoma in USA (Unspecified route) (MyeloRx pipeline, September 2023)
- 14 Sep 2023 Pharmacodynamics and adverse events data from a preclinical trial in Acute myeloid leukaemia and lymphoma released by MyeloRx (MyeloRx pipeline, September 2023)